The FDA clinical hold lift removes a major overhang, but the exploratory data are insufficient to confirm efficacy. The stock may react positively to the regulatory milestone, but the path to approval remains uncertain pending FDA alignment on a new Phase 3 design. Monitor for the FDA meeting outcome and any new trial details in 2027.
Price Chart
Executive Summary
Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension for ARD-101 in Prader-Willi syndrome. The FDA lifted the clinical hold on October 22, 2026, and the company plans to request a meeting to align on a new Phase 3 trial design, with clinical activities expected to resume in 2027. The data show a modest reduction in hyperphagia scores on ARD-101 versus placebo, with a rebound off-drug, but the trial was terminated early with only 67 of 90 planned participants randomized, making all efficacy results exploratory.
Key Facts
- FDA lifted full clinical hold on ARD-101 on October 22, 2026.
- Phase 3 HERO trial terminated early; 67 of 90 planned participants randomized.
- All efficacy data are considered exploratory; trial was not powered for efficacy.
- HQ-CT scores showed a modest reduction with ARD-101 vs placebo by Week 2; scores returned to near baseline after discontinuation.
- OLE participants switching from placebo to ARD-101 had an observed average reduction of 6 points in HQ-CT score.
- One cardiac SAE (Grade 4 polymorphic VT at 800 mg BID) occurred in a participant also taking pitolisant; FDA concurred it was a drug-drug interaction.
- Company plans to request FDA meeting to align on new Phase 3 trial design; expects to resume PWS clinical activities in 2027.
- ARD-101 was generally well tolerated; most adverse events mild to moderate.
Financial Impact
No financial figures reported in the filing. The company is pre-revenue clinical-stage; market cap is $97M.
Risk Factors
- FDA may not agree with proposed Phase 3 program or may require additional studies.
- Exploratory data from an underpowered, terminated trial may not replicate in a new Phase 3.
- Cardiac safety signal (DDI with CYP2D6 substrates) may limit dosing or require monitoring.
- Company may need additional capital to fund a new Phase 3 trial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-429509 |
| Document: ck0001774857-ex99_2.htm | 0001193125-26-429509 |
| Document: ck0001774857-ex99_1.htm | 0001193125-26-429509 |
| Document: 0001193125-26-429509-index-headers.html | 0001193125-26-429509 |
| Document: 0001193125-26-429509-index.html | 0001193125-26-429509 |
| Document: 0001193125-26-429509.txt | 0001193125-26-429509 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers